COMMON STOCK PURCHASE WARRANT CURATIVE BIOTECHNOLOGY, INC.Curative Biotechnology Inc • March 25th, 2022 • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [____________], or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Curative Biotechnology, Inc., a Florida corporation (the “Company”), up to 22,857,143 shares of common stock, of the Company (the “Common Stock”) (subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITY AGREEMENTSecurity Agreement • March 25th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • New York
SECURITY AGREEMENT, dated as of March 2, 2022 (this “Agreement”), between Curative Biotechnology, Inc., a Florida limited liability company (the “Company” or the “Debtor” and collectively with any other Debtor from time to time hereunder, the “Debtors”) and the holders of the Company’s 12.5% Senior Secured Note due March 2, 2023 in aggregate principal amount of $1,142,857.14 (the “Note”), signatory hereto, its endorsees, transferees and assigns (individually referred to as, the “Secured Party” and collectively referred to as, the “Secured Party”). Any terms not defined herein shall have the definition ascribed to them in the Purchase Agreement and Note.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 25th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as March 2, 2022, among Curative Biotechnology, Inc, a Florida corporation whose principal place of business is located at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431 (the “Company”) and the Purchaser identified on the signature pages hereto (including their successors and assigns, the “Purchaser”).
INTELLECTUAL PROPERTY SECURITY AGREEMENTIntellectual Property Security Agreement • March 25th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • New York
This Intellectual Property Security Agreement (“IP Security Agreement”) dated as of March 2, 2022, is made and entered into by and among Curative Biotechnology, Inc., a Florida corporation (the “Company”), any subsidiary of the Company that is a signatory hereto either now joined or joined in the future (such subsidiaries, together with the Company, the “Debtors”), and [_______], as Holder of the 12.5% Senior Secured Notes due March 2, 2023 in aggregate principal amount of $1,142,857.14 (the “Notes”) of the Company.
NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE...Curative Biotechnology Inc • March 25th, 2022 • Biological products, (no disgnostic substances) • New York
THIS 12.5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED NOTE is one of a series of duly authorized and validly issued 12.5% Original Issue Discount Senior Secured Notes of Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431, designated as its 12.5% Original Issue Discount Senior Secured Note due March 2, 2023 (this Note, the “ Note “ and, collectively with the other Notes of such series, the “ Notes”). The Notes shall be convertible into shares of common stock of in the Company in accordance with the terms of the Notes.
LOCK-UP AGREEMENTLock-Up Agreement • March 25th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • New York
Re: Securities Purchase Agreement, dated as of March 2, 2022 (the “Purchase Agreement”), between Curative Biotechnology, Inc., a Florida corporation (the “Company”), and the purchaser signatory thereto (the “Purchaser”)
